Edgewise Therapeutics Inc. Common Stock vs GE Vernova Inc — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.11 (market cap $4.02B), while GE Vernova Inc trades at $911.98 (market cap $250.83B). The key difference: GE Vernova Inc is far larger — about 62.4× Edgewise Therapeutics Inc. Common Stock's market cap, and GE Vernova Inc pays a 0.21% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and GE Vernova Inc for 37 Days on average.
| EWTX | GEV | |
|---|---|---|
Market Cap | $4.02B | $250.83B |
Volume | 1,446,128 | 3,491,026 |
Sector | Health | Industrials |
52-Week High | $48.35 | $1.17K |
52-Week Low | $14.89 | $547.96 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $3.56B | $240.50B |
Dividend Yield | — | 0.21% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong bullish momentum from technical indicators and positive analyst sentiment. The stock shows impressive fundamental performance with 2026 revenue projected at $41.4B and net income of $9.5B, representing a 23.03% profit margin. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and strong backlog growth to $176B, positioning the company to benefit from AI-driven power demand.
The outlook remains positive with 76% analyst buy ratings and a $1,270 consensus price target suggesting 26% upside potential. Key risks include valuation concerns with P/E of 28.79 and EV/EBITDA of 85.64 appearing elevated, along with execution challenges in the wind power segment. The stock's strong cash flow generation and positioning in the AI power infrastructure theme support continued growth prospects despite rich valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →